Bpifrance has acquired a 2% stake in Opella, a Sanofi subsidiary, for between 100 and 150 million euros, aiming to maintain influence despite lacking blocking power on the Board of Directors. The French government has secured guarantees for the preservation of production sites and R&D in France amid concerns over nationalization proposals. Bpifrance"s CEO argues against nationalization, warning it could lead to broader implications for the French chemical industry.
The French government has secured strong guarantees in the sale of a 50% stake in Opella, producer of Doliprane, to American investment fund CD & R, which aims to enhance growth. The agreement includes a €70 million investment in France, job protection, and penalties for production stoppages. Sanofi retains a 48% stake, ensuring continued involvement in Opella's operations.
The French government has reached a tripartite agreement with Sanofi and the American investment fund CD&R for the sale of the Opella subsidiary, which markets Doliprane. The deal includes strong guarantees for maintaining production in France, with a commitment to produce 250 million boxes annually and significant penalties for non-compliance. CD&R will invest €70 million over five years, while the French state will hold a minority stake through Bpifrance to ensure governance and adherence to the agreed conditions.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
